- Brief report
- Open Access
Ambivalence about supervised injection facilities among community stakeholders
Harm Reduction Journalvolume 12, Article number: 26 (2015)
Community stakeholders express a range of opinions about supervised injection facilities (SIFs). We sought to identify reasons for ambivalence about SIFs amongst community stakeholders in two Canadian cities.
We used purposive sampling methods to recruit various stakeholder representatives (n = 141) for key informant interviews or focus group discussions. Data were analyzed using a thematic process. We identified seven reasons for ambivalence about SIFs: lack of personal knowledge of evidence about SIFs; concern that SIF goals are too narrow and the need for a comprehensive response to drug use; uncertainty that the community drug problem is large enough to warrant a SIF(s); the need to know more about the “right” places to locate a SIF(s) to avoid damaging communities or businesses; worry that a SIF(s) will renew problems that existed prior to gentrification; concern that resources for drug use prevention and treatment efforts will be diverted to pay for a SIF(s); and concern that SIF implementation must include evaluation, community consultation, and an explicit commitment to discontinue a SIF(s) in the event of adverse outcomes.
Stakeholders desire evidence about potential SIF impacts relevant to local contexts and that addresses perceived potential harms. Stakeholders would also like to see SIFs situated within a comprehensive response to drug use. Future research should determine the relative importance of these concerns and optimal approaches to address them to help guide decision-making about SIFs.
Public opinion is an important factor to consider in policy making , including drug policy [2, 3]. However, public opinion sometimes runs counter to scientific evidence . This situation is reflected in studies showing that supervised injection facilities (SIFs), designed to reduce injection drug use-related health problems, remain controversial among some stakeholders (e.g., residents, business owners, politicians, and police). Despite evidence to the contrary, some stakeholders believe that SIFs promote initiation of injection drug use, endorse continued drug use at the expense of encouraging entry into drug treatment, and/or promote congregation of people who use and sell drugs which may lead to increased crime in the surrounding area [5, 6]. We previously reported findings showing that public support for SIFs in Ontario, Canada increased between 2003 and 2009 . However, we also reported that the majority of the public continued to hold ambivalent opinions about SIF implementation .
In cities where some stakeholders are currently advocating for SIFs (e.g., New York, San Francisco, Toronto, Ottawa, and Montreal) [8–10], addressing public ambivalence may be important because decision makers are more likely to act when public opinion is supportive of policies . In this brief report, we build upon and supplement previous analyses of ambivalent attitudes within the general public  with qualitative data analyses to identify potential underlying reasons for SIF ambivalence among community stakeholders.
Methods, ethics and consent
In Toronto and Ottawa, we used purposive methods to recruit stakeholders (n = 141; 61 in Toronto and 80 in Ottawa) from varied sectors and groups: health care, addiction services, public health, law enforcement, fire and ambulance services, and housing and social services, as well as local residents and business representatives. To align with our analyses of public opinion data and in the interests of brevity, this sub-analysis of data focuses on these stakeholders. We also recruited people who use drugs (n = 95, including people who inject drugs, people who smoke drugs like crack cocaine, and those who use drugs in both ways) as part of the larger mixed-methods study. Their opinions about supervised consumption design preferences and SIF policy are reported elsewhere [11, 12]. In the study design, we proposed to recruit equal numbers from each city; however, during recruitment a large, multi-stakeholder, community group interested in public safety issues asked the investigators to conduct focus groups with them. Given that this group represented a similar range of stakeholders of interest for our study, we granted their request. This study was approved by the research ethics boards at St. Michael’s Hospital and the Centre for Addiction and Mental Health. We have previously provided more details about participant recruitment methods .
We used an iterative approach to data collection and thematic analyses informed by a grounded theory approach . Members of the research team designed the interview and focus group guides which were pilot tested during initial consultations with participants. Refinements to question wording and new questions were added to the guides based on participant responses during these early interviews and focus groups. We conducted one-on-one key informant interviews (n = 26) and focus group discussions (n = 115 people) between December 2008 and January 2010. All participants provided informed consent, including permission to use anonymized quotes from their data, and were offered a $25 CAD honorarium. All interviews and focus groups were audio-recorded. During all interviews and focus groups, participants were asked questions about the following topics: perceived drug use in their communities; the benefits and drawbacks of SIFs; potential SIF locations and policies; and other approaches to address drug use.
Transcripts were stored and coded using NVivo 8 software. An analytic sub-team developed a codebook that contained key themes and subthemes of interest. Coding meetings were held with sub-team members where any coding discrepancies or suggestions for new codebook themes were discussed and resolved by group consensus.
In this analysis, we focus on seven reasons for ambivalence about SIFs. Sending the “wrong message” and risk of increased drug use and/or injecting were concerns expressed by some participants, but were typically done so in relation to outright dismissal or disagreement with SIFs, rather than ambivalence. Please see Table 1 for a summary of the reasons for ambivalence and supporting excerpts from the data. With the exception of the police in this study, who were uniformly opposed to SIFs , most participants voiced ambivalent opinions about SIF implementation: e.g., “I sit on the fence”, “I’m torn”, and “I’m up in the air with it”. Positive and negative SIF outcomes (e.g., reductions in HIV prevalence in the community; increases in drug-related crime around the facility) were positioned as crucial to the acceptance or rejection of SIFs, and stakeholder ambivalence was partially linked to a lack of knowledge about such outcomes and evidence. Citing lack of sufficient personal knowledge, some stakeholders refused to offer any opinions about SIFs, including a public official in Toronto who said, “I don’t feel like I have all of the information that I would need to make a sound recommendation.”
Ambivalence was also linked to perceptions that SIF goals are too narrow and a comprehensive strategy for drug-related problems, which may include SIFs, is necessary. While some participants could be swayed towards accepting SIFs as part of a comprehensive strategy, there was no consensus about what “comprehensive” included. Suggestions ranged widely, from simply adding new SIF objectives (e.g., include abstinence) to multi-faceted approaches (e.g., increased services for drug use prevention, treatment, primary care, mental health, and housing). While reasons for ambivalence were generally the same in both cities, more Ottawa than Toronto participants spoke about concerns that a SIF would “siphon” away resources for drug treatment. Further, ambivalent stakeholders framed SIFs as a solution for cities said to have “devastating” drug problems (e.g., the Downtown Eastside in Vancouver, Canada) and that did not match the problems they knew about or experienced in their communities.
While ambivalent participants said that there might be a “right place” for SIFs, they did not suggest precise locations but rather excluded locations near their homes or businesses, often out of concern regarding damaging outcomes: e.g., “It's a good idea if it's not in my neighbourhood.” In neighbourhoods where gentrification was attributed to a reduction in local drug-related problems, some participants worried that a SIF(s) would renew these problems. A few ambivalent participants suggested that multiple or mobile SIFs would better address the dispersed nature of drug use in their city and alleviate concerns about congregation of drug users and drug dealing around a SIF(s).
Lastly, before offering their support to SIFs, ambivalent participants stated that they wanted assurances that any facility planning would include rigorous evaluation and opportunities for community consultation regarding SIF continuation or closure.
Our data show that community stakeholders who express ambivalence towards SIFs desire evidence about potential SIF impacts relevant to local contexts and that addresses perceived potential harms. These stakeholders would also prefer to see SIFs as part of a comprehensive drug strategy that ensures dedicated resource allocation for drug use prevention and drug treatment programs. During the focus groups, the moderators were often asked by participants to provide a rationale for SIFs given that needle and syringe programs (NSPs) are available in numerous locations in both Toronto and Ottawa (unpublished observations; Strike, Watson, and Kolla). These questions demonstrate lack of knowledge about the additional benefits of SIFs, over and above NSPs. Also, concerns that a SIF(s) would “siphon” away funds from drug treatment programs suggest lack of understanding of the ways in which SIF services can complement drug treatment programs .
There are several limitations to this study, including the purposive recruitment of participants. However, the aim of this sub-study was to complement existing reports of public opinion  with deeper exploration of stakeholders’ perspectives on SIF implementation. The sample size for this sub-study is large compared to other qualitative studies  and the repetition of reasons for ambivalence across focus groups and key informant interviews suggests that saturation was reached. These features add to the trustworthiness of the data. Nevertheless, our consultations took place in two cities without operational SIFs  and as such these results may not be generalizable to locations where SIFs have already been established. In future surveys of public opinion, including questions about the reasons for ambivalent opinions could provide representative estimates of such opinions and help estimate the relative importance of the reasons for ambivalence we outline above.
For those in favour of SIF implementation, an outstanding question for research and policy remains on the table – how might we better address ambivalence and encourage community stakeholders to support SIFs? A likely and important barrier to changing ambivalent opinions is continued stigma and discrimination towards people who use drugs and harm reduction services [17, 18]. Overcoming this stigmatization will take concentrated effort and broad community education. Making additional gains in SIF acceptance, in particular, appears to need ongoing processes of “policy mobilization” championed by local advocates and experts . Our analysis offers a snapshot of reasons that may underlie SIF ambivalence that may ultimately help or hinder such processes in Canadian and international jurisdictions. The evidence we present is especially timely in Canada where very recently a bill, Bill C-2, that seeks to restrict the opening of new SIFs has received royal assent . The bill outlines a lengthy list of criteria – with emphasis on broad community support – that must be met before the requisite legal exemption for a SIF can be granted [21, 22].
In short, we report evidence from a large, mixed-methods study designed by a group of multidisciplinary experts who received competitive, external funding for this research and who also benefited from access to a public opinion study . These resources and the scope of our study are not easy to replicate. Other communities without access to the same level of scientific expertise and financial resources may face difficulties accumulating the breadth of data required under Bill C-2 or similar legislation that may exist elsewhere which, in turn, may hamper their ability to move forward with evidence-based harm reduction programs.
Supervised injection facilities
Burstein P. The impact of public opinion on public policy: a review and an agenda. Polit Res Q. 2003;56:29–40.
Vernick JS, Burris S, Strathdee SA. Public opinion about syringe exchange programmes in the USA: an analysis of national surveys. Int J Drug Policy. 2003;14:431–5.
Hyshka E, Bubela T, Wild TC. Prospects for scaling-up supervised injection facilities in Canada: the role of evidence in legal and political decision-making. Addiction. 2013;108:468–76.
Ritter A, Lancaster K. Measuring research influence on drug policy: a case example of two epidemiological monitoring systems. Int J Drug Policy. 2013;24:30–7.
Dolan K, Kimber J, Fry C, McDonald D, Fitzgerald J, Trautmann F. Drug consumption facilities in Europe and the establishment of supervised injecting centres in Australia. Drug Alcohol Rev. 2000;19:337–46.
Hedrich D. European report on drug consumption rooms. European Monitoring: Lisbon; 2004.
Strike C, Jairam JA, Kolla G, Millson P, Shepherd S, Fischer B, et al. Increasing public support for supervised injection facilities in Ontario. Canada Addiction. 2014;109:946–53.
Drug Policy Alliance. Supervised injection facilities. http://www.drugpolicy.org/supervised-injection-facilities. Accessed 27 May 2015.
Bayoumi AM, Strike C, Jairam J, Watson T, Enns E, Kolla G, et al. Report of the Toronto and Ottawa Supervised Consumption Assessment Study. Toronto: St. Michael’s Hospital and the Dalla Lana School of Public Health, University of Toronto; 2012.
Jozaghi E. Science versus politics: the need for supervised injection facilities in Montreal. Canada Int J Drug Policy. 2012;23:420–1.
Watson TM, Strike C, Kolla G, Penn R, Bayoumi AM. “Drugs don’t have age limits”: the challenge of setting age restrictions for supervised injection facilities. Drugs Educ Prev Policy. 2015;in press. doi:10.3109/09687637.2015.1034239
Watson TM, Strike C, Kolla G, Penn R, Jairam J, Hopkins S, et al. Design considerations for supervised consumption facilities (SCFs): Preferences for facilities where people can inject and smoke drugs. Int J Drug Policy. 2012;24:156–63.
Corbin J, Strauss A. Basics of qualitative research: techniques and procedures for developing grounded theory. 2nd ed. Los Angeles: Sage Publications; 2008.
Watson TM, Bayoumi A, Kolla G, Penn R, Fischer B, Luce J, et al. Police perceptions of supervised consumption sites (SCSs): a qualitative study. Subst Use Misuse. 2012;47:364–74.
Wood E, Tyndall MW, Zhang R, Montaner JS, Kerr T. Rate of detoxification service use and its impact among a cohort of supervised injecting facility users. Addiction. 2007;102:916–9.
Emmel N. Sampling and choosing cases in qualitative research: a realist approach. Thousand Oaks: Sage; 2013.
Habib S, Adorjany L. Hepatitis C and injecting drug use: the realities of stigmatisation and discrimination. Health Educ J. 2003;62:256–65.
Olsen Y, Sharfstein JM. Confronting the stigma of opioid use disorder – and its treatment. JAMA. 2014;311:1393–4.
McCann E, Temenos C. Mobilizing drug consumption rooms: inter-place networks and harm reduction policy. Health Place. 2015;31:216–23.
CTV News. Bill adding new safe-injection requirements receives royal assent. http://www.ctvnews.ca/politics/bill-adding-new-safe-injection-requirements-receives-royal-assent-1.2434656. Accessed 21 July 2015.
Jozaghi E. Morality versus the scientific evidence: the story behind Bill C-2. Journal of Substance Use. 2016;in press. doi:10.3109/14659891.2014.987837
Zlotorzynska M, Wood E, Montaner JS, Kerr T. Supervised injection sites: prejudice should not trump evidence of benefit. CMAJ. 2013;185:1303–4.
We thank the participants who gave their time and perspectives as part of this study. We also thank the Toronto and Ottawa Supervised Consumption Assessment team: Shaun Hopkins from The Works in Toronto; Janine Luce from the Centre for Addiction and Mental Health (CAMH); Patricia O’Campo, Naushaba Degani, Richard Glazier, and Jennifer Jairam from the Centre for Research on Inner City Health, St. Michael’s Hospital; Benedikt Fischer from Simon Fraser University and CAMH; Susan Shepherd from the Toronto Drug Strategy Secretariat; Peggy Millson from the University of Toronto; Gregory Zaric from the University of Western Ontario; Christopher Smith from the University of Pennsylvania; Lynne Leonard from the University of Ottawa; and Margaret Brandeau and Eva Enns from Stanford University. We received funding from the Ontario HIV Treatment Network. Dr. Bayoumi was supported by a Canadian Institutes of Health Research/Ontario Ministry of Health and Long-Term Care Applied Chair in Health Services and Policy Research. For the first two years of this study, salary and infrastructure support for Dr. Strike were provided by the Ontario Ministry of Health and Long-Term Care. The views expressed in this article are those of the authors and no official endorsement by supporting agencies is intended or should be inferred.
The authors have no competing interests to report.
CS conceived and supervised the study, and prepared the first complete drafts of the manuscript. TMW coordinated the study and assisted with analyses and writing of the manuscript. GK and RP coordinated the study and assisted with analyses. AMB conceived and supervised the study, and assisted with editing of the manuscript. All authors read and approved the final manuscript.